A recent study shows cefalexin is effective for treating uncomplicated cellulitis caused by streptococcal species and methicillin-susceptible Staphylococcus aureus (MSSA). [Mayo Clin Proc2014;89(10):1436–1451]
New drug applications approved by US FDA as of 1 - 15 Feb 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.